Vascular endothelial cell growth factor antagonists and uses...

Details Vascular endothelial cell growth factor antagonists and uses... Vascular endothelial cell growth factor antagonists and uses...

2011-08-30

2011-08-30

Harris, Alana M. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S134100, C424S143100, C424S133100, C424S135100, C424S141100, C424S152100, C424S155100, C424S156100, C424S172100, C424S174100

Reexamination Certificate

active

08007799

ABSTRACT:
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.

REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5306710 (1994-04-01), Wei
patent: 5518999 (1996-05-01), Nakamura et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 6093740 (2000-07-01), Jirousek et al.
patent: 6114320 (2000-09-01), Aiello et al.
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 2005/0053599 (2005-03-01), Van Bruggen et al.
patent: 2005/0244405 (2005-11-01), Van Bruggen et al.
patent: 2007/0110755 (2007-05-01), Ferrara et al.
patent: 2008/0181900 (2008-07-01), Ferrara et al.
patent: 2008/0187534 (2008-08-01), Baca et al.
patent: 2008/0226629 (2008-09-01), Baca et al.
patent: 2008/0299116 (2008-12-01), Van Bruggen et al.
patent: 2008/0311118 (2008-12-01), Van Bruggen et al.
patent: 2009/0081232 (2009-03-01), Kim et al.
patent: 2355976 (1999-12-01), None
patent: 1238986 (2002-09-01), None
patent: 1140173 (2005-08-01), None
patent: 04506659 (1992-11-01), None
patent: 08502514 (1996-03-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 97/40831 (1997-11-01), None
patent: WO 97/44453 (1997-11-01), None
patent: WO 97/49408 (1997-12-01), None
patent: WO 98/16551 (1998-04-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/48795 (1998-11-01), None
patent: WO 98/52577 (1998-11-01), None
patent: WO 00/27414 (2000-05-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/37502 (2000-06-01), None
Jin, D.P., et al. Lymphatic Research and Biology, 7(1): 47-57, 2009.
Kajiya, K. et al., Journal of Investigative Dermatology, 129: 1292-1298, 2009.
Simard, J. M. et al. Lancet Neurol., 6(3): 258-268, 2007.
Severinghaus, J.W., et al. J. Appl. Physiol., 79(2): 375-379, 1995.
Heo, J.H., et al. Free Radical Biology & Medicine, 39: 51-70, 2005.
Adamis et al., 1996,Arch. Ophthalmol., 114:66-71 “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”.
Aiello et al., 1995,Proc. Natl. Acad. Sci. USA, 92:10457-10461 “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins”.
Aiello et al., 1997,Diabetes, 46:1473-1480 “Vascular Endothelial Growth Factor-Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform-Selective Inhibitor”.
Ambati et al. , 1997,Arch. Ophthalmol., 115:1161-1166.
“Elevated γ-Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy”.
Baker et al., 1995,Obstetrics&Gynecology, 86(5):815-821 “Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients With Preeclampsia”.
Barleon, B. et al.,J. Cell Biochem., 1994, 54(1):56-66 “Differential Expression of the Two VEGF Receptors flt and KDR in Placenta and Vascular Endothelial Cells”.
Bennett, B.D. et al., 1991,J. Biol. Chem., 266(34):23060-23067 “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera”.
Berkman, R. et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms”,The Journal of Clinical Investigation, Inc., 91:153-159 (Jan. 1993).
Brauchle et al., 1996,J. Biol. Chem., 271(36):21793-21797 “Ultraviolet B and H2O2Are Potent Inducers of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes”.
Burgess, W.H. et al., 1989,Annu. Rev. Biochem., 58:575-606 “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins”.
Chen, S.T. et al., 1986,Stroke, 17(4):738-743 “A Model of Focal Ischemic Stroke in the Rat: Reproducible Extensive Cortical Infarction”.
Cheng et al., 1997,Proc. Natl. Acad. Sci. USA, 94:12081-12087 “Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121and VEGF165but not VEGF189”.
Chisholm et al., 1995,Mammalian Systems, pp. 1-39 “DNA Cloning 4: A Practical Approach”.
Collins, P.D. et al., 1993,Br. J. Pharmacol., 109:195-199 “Characterization of the Increase in Vascular Permeability Induced by Vascular Permeability Factor in vivo”.
Connolly, D.T. et al., 1989,J. Biol. Chem., 264(33):20017-20024 “Human Vascular Permeability Factor. Isolation from U937 Cells”.
Connolly, D.T. et al., 1989,J. Clin. Invest., 84(5):1470-1478 “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis”.
Criscuolo, 1993,Yale Journal of Biology and Medicine, 66:277-314 “Clinical Neurosciences in the Decade of the Brain Hypotheses in Neuro-Oncology: The Genesis of Peritumoral Vasogenic Brain Edema and Tumor Cysts: A Hypothetical Role for Tumor-Derived Vascular Permeability Factor”.
Davis-Smyth, T. et al., 1996,EMBO J., 15(18):4919-4927 “The Second Immunoglobulin-like Domain of the VEGF Tyrosine Kinase Receptor Flt-1 Determines Ligand Binding and may Initiate a Signal Transduction Cascade”.
de Vries, C. et al., 1992,Science, 255(5047):989-991 “The fms-like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor”.
Detmar, M. et al., 1997,J. Invest. Dermatol., 108(3):263-268 “Hypoxia Regulates the Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) and its Receptors in Human Skin”.
Dobrogowska, D.H. et al., 1998,Journal of Neurocytology, 27:163-173 “Increased Blood-Brain Barrier Permeability and Endothelial Abnormalities Induced by Vascular Endothelial Growth Factor”.
Doldi et al., 1996,The Journal of Reproductive Medicine, 41(11):844-848 “Vascular Endothelial Growth Factor—Expression in Human Vulvar Neoplastic and Nonneoplastic Tissues”.
Dor and Keshet, 1997,Trends in Cardiovascular Med., 7:289-294 “Ischemia-Driven Angiogenesis”.
Ferrara, N. et al., 1987,Proc. Natl. Acad. Sci. USA, 84(16):5773-5777 “Pituitary Follicular Cells Produce Basic Fibroblast Growth Factor”.
Ferrara, N. et al., 1989,Biochem. Biophys. Res. Commun., 161(2):851-858 “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells”.
Ferrara, N. et al., 1991,J. Cell Biochem., 47(3):211-218 “The Vascular Endothelial Growth Factor Family of Polypeptides”.
Ferrara, N. et al., 1992,Endocr. Rev., 13(1):18-32 “Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins”.
Ferrara, N. et al., 1997,Endocr. Rev., 18(1):4-25 “The Biology of Vascular Endothelial Growth Factor”.
Ferrara, N. et al., 1998,Nature Medicine, 4(3):336-340 “Vascular Endothelial Growth Factor is Essential for Corpus Luteum Angiogenesis”.
Fischer et al., 1998,Molecular Brain Research, 60:89-97 “Barbituates decrease the expression of vascular endothelial growth factor in hypoxic cultures of porcine brain derived microvascular endothelial cells”.
Folkman, J. et al., 1989,Nature, 339(6219):58-61 “Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia”.
Gossmann, A. et al., “Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Marker of Tumor Response to Anti-Angiogenic Thera

Affiliated with

Also associated with

Rating

Vascular endothelial cell growth factor antagonists and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial cell growth factor antagonists and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial cell growth factor antagonists and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2702881